D. Van-lammeren-venema, J. C. Regelink, I. I. Riphagen, S. Zweegman, O. S. Hoekstra et al., 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: A systematic review, Cancer, vol.118, issue.8, pp.1971-1981, 2011.

M. Cavo, E. Terpos, C. Nanni, P. Moreau, S. Lentzsch et al., Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group, The Lancet Oncology, vol.18, issue.4, pp.e206-e217, 2017.

E. Zamagni, P. Tacchetti, and M. Cavo, Imaging in multiple myeloma: How? When?, Blood, vol.133, issue.7, pp.644-651, 2019.

E. Zamagni, F. Patriarca, and C. Nanni, Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989?5995., Blood, vol.120, issue.11, pp.2349-2349, 2012.

T. B. Bartel, J. Haessler, T. L. Brown, J. D. Shaughnessy, F. Van-rhee et al., F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma, Blood, vol.114, issue.10, pp.2068-2076, 2009.

P. Moreau, M. Attal, D. Caillot, M. Macro, L. Karlin et al., Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study, Journal of Clinical Oncology, vol.35, issue.25, pp.2911-2918, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01726512

S. Z. Usmani, A. Mitchell, S. Waheed, J. Crowley, A. Hoering et al., Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3, Blood, vol.121, issue.10, pp.1819-1823, 2013.

E. Zamagni, C. Nanni, K. Mancuso, P. Tacchetti, A. Pezzi et al., PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma, Clinical Cancer Research, vol.21, issue.19, pp.4384-4390, 2015.

S. Kumar, B. Paiva, and K. C. Anderson, International Myeloma Working Group Minimal Residual Disease Criteria, Lancet Oncol, vol.17, pp.328-346, 2020.

L. Rasche, S. S. Chavan, O. W. Stephens, P. H. Patel, R. Tytarenko et al., Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing, Nature Communications, vol.8, issue.1, p.268, 2017.

L. Rasche, E. J. Angtuaco, T. L. Alpe, G. H. Gershner, J. E. Mcdonald et al., The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma, Blood, vol.132, issue.1, pp.59-66, 2018.

M. Attal, V. Lauwers-cances, C. Hulin, X. Leleu, D. Caillot et al., Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma, New England Journal of Medicine, vol.376, issue.14, pp.1311-1320, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01557406

M. Cavo, F. Gay, and M. Beksac, Randomized Phase II Study of Bortezomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Multiple Myeloma., Case Medical Research, vol.7, pp.456-468, 2020.

E. Zamagni, C. Nanni, P. Tacchetti, A. Versari, S. Chauvie et al., Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial, Blood, vol.128, issue.22, pp.992-992, 2016.

C. Nanni, A. Versari, S. Chauvie, E. Bertone, A. Bianchi et al., Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe), European Journal of Nuclear Medicine and Molecular Imaging, vol.45, issue.5, pp.712-719, 2017.

R. Boellaard, R. Delgado-bolton, and W. J. Oyen, FDG PET/CT: EANM procedure guidelines for tumour imaging: Version 2.0, Eur J Nucl Med Mol Imaging, vol.42, pp.328-354, 2015.

E. Quak, N. Hovhannisyan, and C. Lasnon, The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: Focus on the Deauville criteria, Haematologica, vol.99, pp.84-85, 2014.

M. Meignan, A. Gallamini, and M. Meignan, Report on the first international workshop on interim-PET-scan in lymphoma, Leuk Lymphoma, vol.50, pp.1257-1260, 2009.

B. G. Durie, J. L. Harousseau, and J. S. Miguel, International uniform response criteria for multiple myeloma, Leukemia, vol.20, pp.1467-1473, 2006.

B. Lausen and M. Schumacher, Maximally selected rank statistics, Biometrics, vol.48, pp.73-85, 1992.

J. Delgado, A. Pereira, and N. Villamor, Survival analysis in hematologic malignancies: Recommendations for clinicians, Haematologica, vol.99, pp.1410-1420, 2014.

S. V. Rajkumar, M. A. Dimopoulos, and A. Palumbo, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, vol.15, pp.538-548, 2014.

J. Bladé, C. F. De-larrea, and L. Rosiñol, Extramedullary involvement in multiple myeloma, Haematologica, vol.97, pp.1618-1619, 2012.

Y. Y. Lu, J. H. Chen, and W. Y. Lin, FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple myeloma: A systematic review and metaanalysis, Clin Nucl Med, vol.37, pp.833-837, 2012.

K. Ghimire, S. V. Rajkumar, and A. Dispenzieri, Incidence and survival outcomes of extramedullary myeloma, Blood, vol.122, p.3141, 2013.

B. Paiva, N. Puig, and M. T. Cedena, Impact of next generation flow minimal residual disease monitoring in multiple myeloma: Results from the PETHEMA/ GEM2012 trial, Blood, vol.130, p.905, 2017.

F. E. Davies, A. Rosenthal, and L. Rasche, Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma, Haematologica, vol.103, pp.1047-1053, 2018.

C. Mesguich, R. Fardanesh, L. Tanenbaum, A. Chari, S. Jagannath et al., State of the art imaging of multiple myeloma: Comparative review of FDG PET/CT imaging in various clinical settings, European Journal of Radiology, vol.83, issue.12, pp.2203-2223, 2014.

T. Carlier, C. Bailly, and R. Leforestier, Prognostic added value of PET textural features at diagnosis in symptomatic multiple myeloma, J Nucl Med, vol.58, 2017.

C. Sachpekids, M. Merz, and A. Kopp-schneider, Quantitative dynamic (18)F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma, Haematologica, vol.104, pp.420-423, 2019.

L. Rasche, E. Angtuaco, J. E. Mcdonald, A. Buros, C. Stein et al., Low expression of hexokinase-2 is associated with false-negative FDG?positron emission tomography in multiple myeloma, Blood, vol.130, issue.1, pp.30-34, 2017.

S. Kircher, A. Stolzenburg, K. M. Kortüm, M. Kircher, M. Da-via et al., Hexokinase-2 Expression in 11C-Methionine?Positive, 18F-FDG?Negative Multiple Myeloma, Journal of Nuclear Medicine, vol.60, issue.3, pp.348-352, 2018.

N. Pandit-taskar, Functional imaging methods for assessment of minimal residual disease in multiple myeloma: Current status and novel immunoPET based methods, Semin Hematol, vol.55, pp.22-32, 2018.

C. Messiou, S. Giles, and D. J. Collins, Assessing response of myeloma bone disease with diffusion-weighted MRI, Br J Radiol, vol.85, pp.1198-1203, 2012.

A. Latifoltojar, M. Hall-craggs, and N. Rabin, Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: Early changes in lesional signal fat fraction predict disease response, Br J Haematol, vol.176, pp.222-233, 2017.

S. L. Giles, C. Messiou, and D. J. Collins, Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma, Radiology, vol.271, pp.785-794, 2014.

. Authors'-disclosures, . Potential, and . Of, About the authors and disclosure of conflicts of interest, Pharmaceutical Care in Digital Revolution, pp.xvii-xxi, 2019.

, Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

E. Zamagni-honoraria-;-janssen-cilag, . Celgene, B. Amgen, and . Myers-squibb, Takeda Consulting or Advisory Role: Celgene, Janssen-Cilag, Amgen, Sanofi Travel, Accommodations, Expenses: Janssen-Cilag, Celgene, Amgen Christina Nanni Honoraria: GE Healthcare, Blue Earth Diagnostics Travel, Accommodations, Expenses: Tema Thomas Carlier Travel, Accommodations, Expenses: Siemens Healthineers Paola Tacchetti Honoraria: Celgene, Janssen-Cilag

A. Versari-travel, Accommodations, Expenses: Novartis Stephane Chauvie Stock and Other Ownership Interests: Dixit srl Speakers' Bureau: Terumo, Sirtex Medical Research Funding: Hoffmann-La Roche Andrea Gallamini Honoraria: Takeda Consulting or Advisory Role: Takeda Barbara Gamberi Honoraria: Celgene Consulting or Advisory Role: Amgen, Celgene, Janssen, Sanofi Margaret Macro Consulting or Advisory Role: Celgene, Amgen, Takeda Research Funding: Takeda (Inst)

C. Amgen, . Janssen, T. Sanofi, . Travel, . Accommodations et al., Laurent Garderet Consulting or Advisory Role: Amgen, Takeda, Novartis, Bristol Myers Squibb Travel, Accommodations, Expenses: Bristol Myers Squibb, Amgen Stefano Fanti Honoraria: Bayer, Sanofi, Astellas Pharma, Janssen, Sofie Travel, Accommodations, Expenses: Bayer, Blue Earth Diagnostics, Sanofi, Astellas Pharma Aurore Perrot Honoraria

T. Janssen-cilag, :. Honoraria, B. Janssen, . Myers-squibb, . Celgene et al., Lionel Karlin Employment: Aguettant (I) Honoraria: Amgen, Celgene, Janssen-Cilag, Takeda Consulting or Advisory Role: Amgen, Celgene, Janssen-Cilag, Takeda, GlaxoSmithKline Travel, Accommodations, Expenses: Amgen